Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

NCT05489276 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Tumors

Interventions

DRUG: TQB2825 injection

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.